Livagon (LL-37) is a short bioactive peptide developed from organ-specific peptide research and investigated for its potential to support liver health,
LL-37 is a naturally occurring human antimicrobial peptide and part of the innate immune system. Synthesized from the precursor protein hCAP18, LL-37 displays broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, and modulates immune responses by attracting immune cells, promoting wound healing, and reducing excessive inflammation. Research suggests LL-37 helps maintain skin and mucosal barrier integrity and plays roles in infection control and tissue repair. Clinical and preclinical studies are exploring therapeutic applications, including topical wound treatments, infection prevention, and immunomodulation, though safety, dosing, and long-term effects require further investigation. As a biologically active peptide, LL-37 holds promise but should be considered experimental outside regulated medical settings.
Livagon (LL-37) is a short bioactive peptide developed from organ-specific peptide research and investigated for its potential to support liver health,
LL-37 is a naturally occurring human antimicrobial peptide and part of the innate immune system. Synthesized from the precursor protein hCAP18, LL-37 displays broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, and modulates immune responses by attracting immune cells, promoting wound healing, and reducing excessive inflammation. Research suggests LL-37 helps maintain skin and mucosal barrier integrity and plays roles in infection control and tissue repair. Clinical and preclinical studies are exploring therapeutic applications, including topical wound treatments, infection prevention, and immunomodulation, though safety, dosing, and long-term effects require further investigation. As a biologically active peptide, LL-37 holds promise but should be considered experimental outside regulated medical settings.
